Menu
GeneBe

AICDA

activation induced cytidine deaminase, the group of Apolipoprotein B mRNA editing enzyme catalytic subunits

Basic information

Region (hg38): 12:8602154-8613242

Links

ENSG00000111732NCBI:57379OMIM:605257HGNC:13203Uniprot:Q9GZX7AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • hyper-IgM syndrome type 2 (Definitive), mode of inheritance: AR
  • hyper-IgM syndrome type 2 (Strong), mode of inheritance: AR
  • hyper-IgM syndrome type 2 (Definitive), mode of inheritance: AR
  • hyper-IgM syndrome type 2 (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Immunodeficiency with hyper-IgM, type 2ARAllergy/Immunology/InfectiousIndividuals have elevated serum IgM levels and absent IgG, IgA, and IgE, and are thus highly susceptible to severe bacterial infections (eg, bacterial respiratory and GI infections), such that antiinfectious prophylaxis (including with IVIG, which has been reported to be effective) and early and aggressive treatment of infections may be beneficial; Individuals may also have autoimmune and inflammatory manifestions, some of which may benefit from early knowledge and interventions, including hemolytic anemia and immune thrombocytopeniaAllergy/Immunology/Infectious11007475; 14962793; 15358621; 19575287; 21192628

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the AICDA gene.

  • Hyper-IgM syndrome type 2 (190 variants)
  • not provided (36 variants)
  • not specified (8 variants)
  • Hyperimmunoglobulin M syndrome (5 variants)
  • Inborn genetic diseases (4 variants)
  • AICDA-related condition (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the AICDA gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
22
clinvar
4
clinvar
26
missense
5
clinvar
7
clinvar
61
clinvar
2
clinvar
75
nonsense
4
clinvar
4
clinvar
2
clinvar
10
start loss
0
frameshift
0
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
3
clinvar
3
splice region
3
4
1
8
non coding
32
clinvar
26
clinvar
18
clinvar
76
Total 9 14 96 50 22

Highest pathogenic variant AF is 0.000177

Variants in AICDA

This is a list of pathogenic ClinVar variants found in the AICDA region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
12-8602350-G-A Hyper-IgM syndrome type 2 Likely benign (Jan 12, 2018)127036
12-8602482-A-G Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)881009
12-8602580-G-A Hyper-IgM syndrome type 2 Likely benign (Jan 12, 2018)881010
12-8602590-T-C Hyper-IgM syndrome type 2 Benign (Jan 13, 2018)310548
12-8602600-A-G Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)881011
12-8602618-C-A Hyper-IgM syndrome type 2 Benign (Jan 13, 2018)310549
12-8602622-G-T Hyper-IgM syndrome type 2 Likely benign (Jan 13, 2018)310550
12-8602829-C-T Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)881012
12-8602830-T-TC Hyperimmunoglobulin M syndrome Uncertain significance (Jun 14, 2016)310551
12-8602831-T-C Hyper-IgM syndrome type 2 Uncertain significance (Jan 12, 2018)882366
12-8602904-T-C Hyper-IgM syndrome type 2 Uncertain significance (Jan 12, 2018)882367
12-8602971-C-G Hyper-IgM syndrome type 2 Uncertain significance (Jan 12, 2018)882368
12-8602987-C-T Hyper-IgM syndrome type 2 Benign (Jan 13, 2018)310552
12-8602988-G-A Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)882369
12-8603022-G-A Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)310553
12-8603058-T-G Hyper-IgM syndrome type 2 Uncertain significance (Jan 12, 2018)882370
12-8603071-T-C Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)310554
12-8603078-G-A Hyper-IgM syndrome type 2 Benign (Jan 13, 2018)310555
12-8603111-G-A Hyper-IgM syndrome type 2 Uncertain significance (Jan 12, 2018)310556
12-8603145-T-C Hyper-IgM syndrome type 2 Likely benign (Jan 12, 2018)310557
12-8603146-T-C Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)882638
12-8603147-T-C Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)310558
12-8603148-T-C Hyper-IgM syndrome type 2 Uncertain significance (Jan 13, 2018)310559
12-8603178-T-C Hyper-IgM syndrome type 2 Uncertain significance (Jan 12, 2018)310560
12-8603195-G-A Hyper-IgM syndrome type 2 Benign (Jan 12, 2018)310561

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
AICDAprotein_codingprotein_codingENST00000229335 510706
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.000009210.5571247730221247950.0000881
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.34891320.6730.00001031285
Missense in Polyphen3054.5430.55003548
Synonymous-1.235847.31.230.00000325384
Loss of Function0.755911.80.7636.78e-7117

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001250.000123
Ashkenazi Jewish0.000.00
East Asian0.0002780.000278
Finnish0.000.00
European (Non-Finnish)0.00007740.0000706
Middle Eastern0.0002780.000278
South Asian0.0001720.000163
Other0.0001650.000165

dbNSFP

Source: dbNSFP

Function
FUNCTION: Single-stranded DNA-specific cytidine deaminase. Involved in somatic hypermutation (SHM), gene conversion, and class-switch recombination (CSR) in B-lymphocytes by deaminating C to U during transcription of Ig-variable (V) and Ig-switch (S) region DNA. Required for several crucial steps of B-cell terminal differentiation necessary for efficient antibody responses (PubMed:18722174, PubMed:21385873, PubMed:21518874, PubMed:27716525). May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation (PubMed:21496894). {ECO:0000269|PubMed:18722174, ECO:0000269|PubMed:21385873, ECO:0000269|PubMed:21496894, ECO:0000269|PubMed:21518874, ECO:0000269|PubMed:27716525}.;
Disease
DISEASE: Immunodeficiency with hyper-IgM 2 (HIGM2) [MIM:605258]: A rare immunodeficiency syndrome characterized by normal or elevated serum IgM levels with absence of IgG, IgA, and IgE. It results in a profound susceptibility to bacterial infections. {ECO:0000269|PubMed:11007475, ECO:0000269|PubMed:14962793, ECO:0000269|PubMed:23803409, ECO:0000269|PubMed:26545377, ECO:0000269|PubMed:27716525}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Primary immunodeficiency - Homo sapiens (human);Intestinal immune network for IgA production - Homo sapiens (human);Pyrimidine nucleotides nucleosides metabolism;IL4-mediated signaling events (Consensus)

Recessive Scores

pRec
0.442

Intolerance Scores

loftool
0.491
rvis_EVS
0.04
rvis_percentile_EVS
56.92

Haploinsufficiency Scores

pHI
0.137
hipred
Y
hipred_score
0.518
ghis

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.964

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Aicda
Phenotype
hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; neoplasm; digestive/alimentary phenotype; immune system phenotype; cellular phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);

Gene ontology

Biological process
mRNA processing;cytidine deamination;negative regulation of transposition;somatic diversification of immunoglobulins;somatic hypermutation of immunoglobulin genes;cytidine to uridine editing;B cell differentiation;regulation of nuclear cell cycle DNA replication;defense response to bacterium;isotype switching;negative regulation of single stranded viral RNA replication via double stranded DNA intermediate;defense response to virus;DNA cytosine deamination;cellular response to lipopolysaccharide;DNA demethylation;negative regulation of methylation-dependent chromatin silencing
Cellular component
exosome (RNase complex);P-body;nucleus;cytoplasm
Molecular function
RNA binding;cytidine deaminase activity;protein binding;zinc ion binding;ubiquitin protein ligase binding;identical protein binding